KEYTRUDA Combination Triples Response Rate in Ovarian Cancer, Shows Solid Phase 2a Data at ASCO
MRK sits 54% above its 52-week low of $75.4.
Summary
BioInvent announced positive Phase 2a clinical trial data for its BI-1808 antibody in combination with Merck's KEYTRUDA for advanced ovarian cancer at ASCO. The combination achieved a 24% objective response rate (ORR) and 56% disease control rate (DCR) in heavily pretreated patients, tripling the historical 8% ORR of KEYTRUDA monotherapy. This strong early data suggests a significant improvement in efficacy for KEYTRUDA in a difficult-to-treat cancer, potentially expanding its market and extending its lifecycle. Another data readout is expected in H2 2026.
At the time of this announcement, MRK was trading at $115.80 on NYSE in the Life Sciences sector, with a market capitalization of approximately $286.2B. The 52-week trading range was $75.40 to $125.14. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: MFN by Modular Finance.